Research
Molecular
Dapagliflozin is a selective SGLT2 inhibitor approved to improve glycemic control in adults with type 2 diabetes.
Dapagliflozin can be considered as a treatment option for managing blood sugar levels in adults with type 2 diabetes.
StrongSupportsmedium confidence
Dapagliflozin (Farxiga, AstraZeneca) is a selective SGLT2 inhibitor approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.
Why this rating
The claim is supported by clinical trial data mentioned in the abstract.
Source
Dapagliflozin: A new sodium–glucose cotransporter 2 inhibitor for treatment of type 2 diabetes
Eva Vivian · American Journal of Health-System Pharmacy · 2015
DOI 10.2146/ajhp140168
reviewCited 44×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Molecular
- QRISK decreased markedly after weight loss from 18.9 ± 2.2% to 11.2 ± 1.6%, p < 0.0001.Strong
- Normalization of 10-year cardiovascular risk and heart age is possible after substantial dietary weight loss and remission of T2DM.Strong
- The Low-Fat Plus diet resulted in a greater reduction in total cholesterol compared to the Low-Fat diet, with changes of -0.46 mmol/L (-17.6 mg/dL) versus -0.24 mmol/L (-9.2 mg/dL) respectively (P = 0.01).Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →